Navigation Links
Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June
Date:4/9/2008

to boost immune responses. Favrille's unique and proprietary manufacturing process, which includes an insect cell (baculovirus) expression system, allows for the manufacture of Specifid for delivery to patients in as few as eight weeks. Data presented at the American Society of Hematology Annual Meeting in December 2007 showed that Id-KLH produced via insect cells results in a more immunogenic response compared to Id-KLH produced in a traditional mammalian cell manufacturing process. Also, unlike other Id-KLH active immunotherapies in development, Specifid is intended for use as a chronic therapy and is administered until the patient's disease progresses.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, Specifid (mitumprotimut-T, formerly FavId), is a patient-specific, active immunotherapy based upon unique genetic information extracted from a patient's tumor. Specifid is currently under investigation in a Phase 3 registration trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

The preliminary, blinded clinical data reported from time to time prior to the release of the final results of Favrille's Phase 3 registration trial have not been audited and have been taken from databases that have not been reconciled against medical records kept at the clinical sites or that may not include the most current information on patient disease progressions. The data released may not be indicative of the final results of Favrille's Phase 3 registration trial Failure can oc
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
2. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
3. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
4. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
5. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
6. Medarex Announces Ipilimumab Program Continues to Move Forward
7. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
8. CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors
9. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
10. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
11. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... 18, 2014  In a policy paper ... the nation,s largest lesbian, gay, bisexual and transgender ... of Truvada for Pre-Exposure Prophylaxis (PrEP). PrEP is ... prevent the spread of a disease or infection ... name anti-HIV drug combination currently approved for PrEP, ...
(Date:10/17/2014)... NORWALK, Conn. , Oct. 17, 2014 UBM ... , a leading online community and information resource for ... Parkinson disease and Alzheimer disease , with discussions ... Up to 1 million Americans have Parkinson disease , ... muscular dystrophy, or Lou Gehrig disease. Diagnosis can ...
(Date:10/17/2014)... Oct. 17, 2014 A victim of medical negligence ... doctor with a history of alcohol abuse, a physician ... on Prop 46 today, highlighting how Prop 46 will identify ... testing. The ad pictures a doctor drinking ... To ER."  Proposition 46 will enact the first law in ...
Breaking Medicine Technology:HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4
(Date:10/18/2014)... October 19, 2014 Mercy’s student mentoring ... report on programs that help college students succeed. ... software and services, published the recent paper, “Retention and ... and Mercy is one of six higher education institutions ... fall to fall retention rates for first-time, full-time students ...
(Date:10/18/2014)... (PRWEB) October 19, 2014 Recently, BamboofloorChina.com, one ... market, has added a new assortment of bamboo floorings ... offering huge price cuts for worldwide clients now, up to ... of useful and durable items for sale now; most of ... decades. Clients can find more than 100 different kinds of ...
(Date:10/18/2014)... October 2014 All humans have a natural opioid system ... ECNP Congress in Berlin, has found that the opioid ... normal healthy volunteers. The work was carried out by ... and was funded by the Medical Research Council. This ... Neuropsychopharmacology congress in Berlin., Gambling is a widespread behaviour ...
(Date:10/18/2014)... NY (PRWEB) October 18, 2014 Ticket Down is ... prices have eased considerably for this year's World Series. ... in the World Series this year. This determined team has ... The San Francisco Giants have had better luck in terms of ... 2010, 1954, 1933, 1922, 1921 and 1905. This team ...
(Date:10/18/2014)... 18, 2014 Market Research ... Industry, 2009-2019 is a professional and in-depth ... Chondroitin sulfate industry. The report firstly reviews ... its classification, application and manufacturing technology. The ... manufacturers of Chondroitin sulfate listing their product ...
Breaking Medicine News(10 mins):Health News:Mercy’s PACT Student Mentoring Program Recognized for Helping College Students Succeed 2Health News:Brand New Bamboo Floorings Now Unveiled By BamboofloorChina.com, A Distinguished Supplier In The Market 2Health News:Pathological gambling is associated with altered opioid system in the brain: Reduced feeling of euphoria when compared to healthy volunteers 2Health News:2014 World Series Tickets: Giants vs. Royals World Series Ticket Prices Have Eased Substantially 2Health News:Chondroitin Sulfate Industry Global & Chinese Forecast to 2019 Now Available at RnRMarketResearch.com 2Health News:Chondroitin Sulfate Industry Global & Chinese Forecast to 2019 Now Available at RnRMarketResearch.com 3Health News:Chondroitin Sulfate Industry Global & Chinese Forecast to 2019 Now Available at RnRMarketResearch.com 4
... 22 Val J. Halamandaris,President of the National Association ... Americans to commemorate the power of caring, both at ... National Home,Care and Hospice Month., "It is highly ... day to,celebrate the nurses, therapists, aides and other providers ...
... 22, 2007 The Autism Consortium, a group of ... and enhancing clinical care for autism, announced today that ... Spectrum Disorders (ASD) through its Autism Gene Discovery Project ... database that autism researchers around the world can use. ...
... 2007Four Mary Ann Liebert, Inc. journals are participating in ... a special worldwide publishing event on October 22, 2007 ... and human development. The Council of Science Editors has ... of key journals throughout the world, including those published ...
... giveaway, researcher says, , , MONDAY, Oct. 22 (HealthDay News) -- ... lung doctor says a common device can determine whether someone ... could be used to ferret out people who hide a ... also help show patients what smoking is doing to their ...
... (Chicago, IL, October 22, 2007) A new study shows ... vary with age. The study presented at CHEST 2007, the ... Chest Physicians (ACCP), found that smokers over age 65 reported ... a major health problem, while smokers under age 65 reported ...
... important advances toward a therapeutic device that has the ... blood stream and treat them. Among other applications, such ... tissues, or signal stem cells to differentiate. , Their ... cells down as they flow through blood vessels. As ...
Cached Medicine News:Health News:U.S. Celebrates National Home Care and Hospice Month in November 2Health News:Autism Consortium releases data on genes involved in autism to researchers worldwide 2Health News:Autism Consortium releases data on genes involved in autism to researchers worldwide 3Health News:Autism Consortium releases data on genes involved in autism to researchers worldwide 4Health News:Global theme issue on poverty and human development 2Health News:Blood Test Catches Secret Smokers 2Health News:Blood Test Catches Secret Smokers 3Health News:Age affects motivation for quitting smoking 2Health News:MIT works toward novel therapeutic device 2Health News:MIT works toward novel therapeutic device 3
Digital Ultrasonic Diagnostic Imaging System...
...
Pefakit PiCT DxS Diluent for Determination of Total Heparin...
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Medicine Products: